Category: Uncategorized

As of October 1, 2026 (KST)

Let’s look at why siRNA deals keep coming—and how to choose among the companies. Start with why PCSK9 is relatively accessible and when an early lead in a new target such as ALK7 can create value. Then compare the delivery leaders with the clinical and business conditions facing Silence, Wave, and Vir.

In this article

Verified Data

Small interfering RNA, or siRNA, lowers the messenger RNA (mRNA) that carries instructions for making a particular protein. Inside a cell, its guide strand joins the RNA-induced silencing complex, or RISC, and directs Ago2 to cut the target mRNA. This is different from gene editing that permanently changes DNA itself. [1]

The starting point is getting the drug into the right cells. A delivery tag called GalNAc uses the ASGPR receptor on liver cells. Reducing a protein made in the liver can help address disease in another organ. So a drug described as a heart-disease treatment hasn’t necessarily demonstrated direct delivery into heart cells. [1,11]

Alnylam’s AMVUTTRA (vutrisiran) is a useful example. This siRNA reduces production of transthyretin, or TTR. Its March 2025 US label includes adults with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM), with an indication to reduce cardiovascular deaths, cardiovascular hospitalizations, and urgent heart-failure visits. It’s a benchmark for connecting delivery to actual disease-related events. [11]

Getting inside a cell isn’t the end of the job. siRNA trapped in an endosome—a compartment inside the cell—must escape to become active. Original studies show that cellular uptake, changes in endosomal membranes, and release of functional siRNA are distinct steps. [23,24]

We need to separate the evidence, too. Was the drug detected in tissue? Did target mRNA or a related protein decline? Did patients’ function or disease outcomes improve? Those are different questions. A biopsy samples a small piece of tissue; a result at one site doesn’t establish uniform delivery to every cell throughout the body. [27,29,30,22]

Why PCSK9 Is a Good Starting Point for siRNA

LDL receptors help remove LDL cholesterol from the blood. PCSK9 interferes with those receptors’ recycling. Reducing PCSK9 production in hepatocytes—the liver’s main functional cells—leaves more receptors available to clear LDL. The delivery destination, protein mechanism, and measurable blood marker line up unusually well. [63]

Human genetics provides another starting point. Research involving the Dallas Heart Study linked naturally occurring loss-of-function PCSK9 variants with lower LDL cholesterol. That gives drug developers a reason to try to reproduce part of the biology. It doesn’t mean lifelong genetic variation proves the long-term safety of a drug started in adulthood. [64,65]

Novartis’s LEQVIO (inclisiran) uses GalNAc to reach hepatocytes and reduce PCSK9 mRNA. ASGPR provides a validated route into these cells. That doesn’t make every liver cell easy to reach, and endosomal escape still matters. Liver delivery reduces one source of uncertainty; it doesn’t make drug development easy. [63,1,23,24]

LEQVIO is given initially, again at three months, and then every six months. Its August 2026 US label covers LDL-cholesterol reduction. REPATHA (evolocumab), a PCSK9 antibody, has an indication for reducing major cardiovascular events. Evidence supporting the target and evidence that inclisiran itself prevents those events are different things. [63,66]

Competition already includes statins and injectable antibodies. On July 17, 2026, the FDA also approved Merck’s once-daily oral PCSK9 inhibitor Lipfendra (enlicitide). A new siRNA has to earn its place through treatment burden, access, and price as well as LDL reduction. [63,66,67]

The deals below illustrate the interest in delivery technology. These are selected examples from 2021–2026, not a calculation of industry-wide growth in deal count or value. Amounts are in US dollars and reflect the terms announced at the time. [2,4,5,6,7,8]

Announcement date	Deal	Technology or assets sought	Upfront cash or acquisition consideration	Amounts to keep separate
November 18, 2021	Novo Nordisk → Dicerna	GalXC RNAi platform and pipeline	Cash acquisition at approximately $3.3 billion in equity value	A company acquisition, not a licensing upfront payment
July 24, 2023	Roche ↔ Alnylam	Hypertension candidate zilebesiran	$310 million upfront	Conditional development, regulatory, and commercial payments
November 26, 2024	Sarepta ↔ Arrowhead	Muscle, central nervous system, and lung programs	$500 million upfront cash	$325 million equity investment; $250 million paid over five years; up to $300 million in near-term milestones; approximately $10 billion in potential future milestones
May 14, 2025	AbbVie ↔ ADARx	siRNA options in neuroscience, immunology, and oncology	$335 million upfront	Additional conditional option fees, milestones, and other payments
September 2, 2025	Novartis ↔ Arrowhead	Preclinical ARO-SNCA and additional targets	$200 million upfront	Up to $2 billion in milestones, plus royalties
October 26, 2025	Novartis → Avidity	Muscle delivery and neuromuscular programs	$12 billion in cash consideration	Company acquisition after separation of early cardiovascular assets

The Sarepta agreement’s initial $825 million consists of $500 million in cash and a $325 million equity investment. An equity investment gives the investor an ownership stake. Milestones are payments tied to conditions being met. The maximum deal value isn’t cash already in the bank. [5]

The scope of these deals has expanded from liver platforms to hypertension, muscle, and the central nervous system. These examples show interest in broader applications. They don’t establish that every siRNA company becomes more valuable together. [2,4,5,7,8]

Background Reporting

Andrew Marshall also covered dealmaking interest in RNA delivery and manufacturing in a 2025 Nature Biopharma Dealmakers article. The material available here was mainly the public introduction, and the article covers RNA broadly. It isn’t evidence for an industry-wide growth rate specific to siRNA. [20]

Three Groups of Targets to Watch

Let’s divide the target landscape into three groups: hepatic targets with approved products and clinical candidates; newer hepatic metabolic and signaling targets; and targets outside the liver that face direct-delivery barriers. The 23 rows below use US approval status and the cited labels or 2026 company disclosures. Historical validation and an unproven patient benefit shouldn’t receive the same weight.

Hepatic target	Disease and site of action	Company, asset, and established stage	What investors should distinguish
PCSK9	Reduces hepatic production to lower blood LDL	Novartis LEQVIO: US approved	Competition from antibodies, statins, and oral enlicitide; LDL lowering versus event prevention [63,66,67]
APOC3	Reduces hepatic production to control triglycerides	Arrowhead REDEMPLO: approved for adults with FCS	Rare familial disease approval versus broader severe hypertriglyceridemia development; Ionis ASO competition [14–17]
TTR	Liver-produced protein that deposits in the heart and nerves	Alnylam AMVUTTRA: US approved	Benefit in heart disease doesn’t establish direct heart-cell delivery; competition from stabilizers [11,21]
LPA	Hepatic apo(a) production contributes to circulating Lp(a)	Silence zerlasiran: phase 3-ready, seeking a partner; Amgen olpasiran and Lilly lepodisiran: phase 3	Read alongside pelacarsen’s September cardiovascular-outcomes failure [43–46]
AGT	Hepatic angiotensinogen production affects blood-pressure regulation	Alnylam/Roche zilebesiran: in development	KARDIA-3 missed its overall statistical goal; established oral blood-pressure drugs compete [4,13]
ANGPTL3	Hepatic lipid-metabolism protein; homozygous familial hypercholesterolemia (HoFH)	Arrowhead zodasiran: phase 3 YOSEMITE; company announced completed enrollment in July	Regeneron’s antibody EVKEEZA is approved in the same HoFH setting [68,69]
TMPRSS6	Changes hepatic iron regulation to address excess red-cell production in PV	Silence divesiran: phase 2 SANRECO	Phlebotomy and blood-count measures versus thrombosis and survival; not direct bone-marrow delivery [18,40]
HAO1	Hepatic oxalate-production pathway; primary hyperoxaluria type 1 (PH1)	Alnylam OXLUMO (lumasiran): approved	Historical validation of targeting liver production to address kidney disease [70]
LDHA	Another hepatic oxalate-producing enzyme; PH1	Novo Nordisk RIVFLOZA (nedosiran): approved	PH1 in patients age 2 and older with relatively preserved kidney function; not approval for every PH subtype [71]
ALAS1	Hepatic enzyme; acute hepatic porphyria (AHP)	Alnylam GIVLAARI (givosiran): approved in adults	A validated target still requires monitoring for hepatic and renal toxicity [72]

Next come newer liver targets and pathways. Metabolic dysfunction-associated steatohepatitis (MASH), alcohol-related liver disease (ALD), and inherited protein accumulation all involve the liver. They still have different patient populations and endpoints. Results in one setting can’t simply be carried into another. [73,74,31,75,76]

New hepatic target or pathway	Disease and approach	Company, asset, and established stage	Competition and remaining tests
INHBE / Activin E	Changes a hepatic signal to affect fat metabolism	Arrowhead ARO-INHBE: phase 1/2a; WVE-007 combination: phase 2a initiated; Alnylam ALN-6222: phase 1 initiated; Silence SLN098: preclinical	Companies pursuing the same target are at different stages; replacement of or combination with GLP-1 drugs requires separate proof [25,51–53,12]
PNPLA3	Fatty liver and MASH, in the context of the I148M genotype	Madrigal MGL-0795, formerly ARO-PNPLA3: monotherapy phase 1 completed	Madrigal holds an exclusive global asset license and is pursuing combination with resmetirom; don’t extend genotype-specific results to all MASH [73,77]
HSD17B13	Enzyme associated with liver disease	GSK gatuzosiran/GSK4532990: ALD phase 2 in its second-quarter 2026 report	Distinguish historical MASH research from current ALD development; not a halt to the entire asset [74]
SERPINA1 / mutant Z-AAT	Hepatic accumulation associated with alpha-1 antitrypsin (AAT) deficiency	Takeda/Arrowhead fazirsiran: phase 3	Reducing toxic liver deposits differs from replacing a lung-protective protein; distinguish US profit sharing from royalties outside the US [31]
HBV RNA	Viral RNA in infected hepatocytes, not a single human gene	Vir’s Alnylam-licensed elebsiran plus its antibody tobevibart	Reduces HBsAg needed by HDV; an HBV cure and HDV trial results are different claims [56,57,61]
GPR146	Exploratory hepatic metabolic and lipid regulation	Silence SLN365: preclinical	No demonstrated human pharmacologic effect; don’t value it like a clinical asset [51]

US competition in MASH already includes the GLP-1 drug WEGOVY and the oral thyroid hormone receptor-beta agonist REZDIFFRA. Their accelerated approvals cover adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2–F3. A PNPLA3 drug could add value in a specific genetic population or a combination, but that additional value still needs evidence. [75,76,77]

Outside the liver, the question becomes whether the drug reaches the relevant fat cells, diseased muscle, or brain cells. These are research directions and evidence milestones, not a list of established clinical successes. [25–30,22,31,32]

Extrahepatic target	Tissue and disease	Company, asset, and evidence stage	Boundary of the evidence
ACVR1C / ALK7	Adipocytes; obesity	Arrowhead ARO-ALK7: phase 1/2a; human adipose-tissue data in January 2026	Early evidence of direct adipose delivery, not confirmation of sustained weight loss [25,78]
APP	CNS; Alzheimer’s-related development	Alnylam mivelsiran: company reported completed phase 2 enrollment in cerebral amyloid angiopathy (CAA) and phase 2 initiation in Down syndrome-associated Alzheimer’s disease (DSAD)	Different patient populations; Alnylam holds global rights; fluid-protein changes differ from cognitive or bleeding benefits [28,29,12]
HTT	CNS; Huntington’s disease	Alnylam/Regeneron ALN-HTT02: early clinical development	Molecular changes versus functional benefit; company presentation timing appears below [12,28]
MAPT / tau	CNS; early Alzheimer’s disease	Arrowhead ARO-MAPT: phase 1/2a; Alnylam ALN-5288: preclinical data and phase 1 design disclosed	Human results for Arrowhead’s systemic subcutaneous approach remain ahead; distinguish published preclinical blood-brain barrier evidence [32,12]
DUX4	Skeletal muscle; FSHD1	Sarepta SRP-1001, originating at Arrowhead: phase 1/2a	Drug detection and downstream gene signals in muscle biopsies versus functional benefit [26,27,31]
DMPK / toxic RNA	Skeletal muscle; DM1	Sarepta SRP-1003; Novartis del-desiran failed phase 3 HARBOR	The gap between delivery or mRNA reduction and patient function [22,26,30]
RAGE	Lung; inflammatory respiratory development	Arrowhead inhaled ARO-RAGE: phase 2 in its 2026 filing	Historical reductions in lavage-fluid protein don’t establish current respiratory clinical efficacy [33,31]

The ALK7 and INHBE distinction matters. ACVR1C encodes ALK7, a receptor on fat cells. INHBE encodes Activin E, a liver-derived signal. They are different nodes in a signaling axis. Arrowhead’s direct ALK7 approach and the hepatic INHBE approaches pursued by Wave, Silence, and Alnylam address related fat biology, but require different delivery evidence. [79,78,12,25,49,51]

Human loss-of-function INHBE variants have been associated with a favorable fat-distribution pattern. That’s a biological rationale, not proof that an INHBE drug produces weight loss, preserves muscle, or remains safe over years. Compare the companies by how much of that gap their human data have closed. [79,78]

How Far Has Delivery Come?

The key comparison is the human evidence in each tissue, rather than the platform name. The table below maps representative technologies and assets. It isn’t an efficacy ranking based on knockdown percentages from different tissues and diseases. Read each row alongside its evidence date and limitations.

Company and technology	Target tissue and delivery approach	Human evidence	Main unresolved question	Economic rights and investment exposure
Arrowhead (ARWR)	TRiM-based approaches for fat, lung, and other tissues; carriers must be distinguished by tissue	ARO-ALK7 adipose-tissue mRNA data, January 2026; lung-lavage protein data after inhaled ARO-RAGE, July 2023 data	Do pharmacologic effects in small samples translate into repeat-dose safety and patient benefit?	Platform developer, but partner rights vary by asset [25,31,33]
Alnylam (ALNY)	Liver GalNAc and lipid nanoparticles; C16 conjugates for the central nervous system	Disease-event evidence from approved liver-directed products; early cerebrospinal-fluid protein reductions after intrathecal mivelsiran	Do brain-related biomarkers translate into cognitive or functional improvement?	ALNY holds global rights to mivelsiran; ALN-HTT02 is a Regeneron collaboration [11,28,29]
Sarepta (SRPT)	Arrowhead-origin integrin-targeting ligand–siRNA approach for muscle	Drug exposure and downstream gene changes in SRP-1001 muscle biopsies, March 25, 2026 company presentation	Confirmation of repeat-dose performance and functional benefit	Exclusive global licenses to the relevant assets; don’t count the same technology twice across ARWR and SRPT [26,27,31]
Novartis (NVS)/Avidity	TfR1 antibody–siRNA conjugates for muscle	Muscle DMPK mRNA reduction in MARINA; subsequent failure on HARBOR’s phase 3 primary endpoint	The gap between molecular effects and functional effects	Acquisition completed in February 2026; exposure is through NVS, not an independent Avidity stock [9,10,30,22]
Novartis/DTx	FALCON fatty acid–siRNA approach aimed at peripheral-nerve Schwann cells	Acquisition-era evidence reviewed here is preclinical	Insufficient confirmation of its latest human development stage in 2026	Acquired by NVS in 2023; not presented as an independently listed investment [35]
City/Biogen	City RNAi and Biogen delivery technology; research on systemic CNS administration	No human delivery results for this collaboration in the reviewed material	Will systemic administration produce the intended pharmacologic effect in humans?	City is private; Biogen handles development and commercialization of collaboration programs [34]
ADARx/AbbVie	Combining RNA technology with antibody and tissue-delivery capabilities	No extrahepatic human delivery results established by the agreement	Will the collaboration produce candidates and clinical validation?	Licensing option agreement; the upfront payment isn’t proof of clinical success [6,36]

Start with Arrowhead’s delivery to fat. On January 6, 2026, the company reported interim phase 1/2a data for ARO-ALK7: four adults with obesity in the 200 mg group had an average 88% reduction in adipose-tissue ALK7 mRNA at week eight. That’s closer to the target tissue than a blood-protein measurement. But it’s four people, and the figure wasn’t presented as a placebo-adjusted reduction. [25]

ARO-INHBE targets the liver, while ARO-ALK7 targets fat cells. A drug that affects fat isn’t necessarily delivered directly into it. In the January interim ARO-ALK7 analysis, the company reported no serious adverse events or adverse-event-related discontinuations. A small, early sample doesn’t establish long-term repeat-dose safety or improvements in weight and metabolic disease. [25]

In the lung, there’s inhaled ARO-RAGE. In July 2023 data, Arrowhead reported lower sRAGE protein in human bronchoalveolar lavage fluid—fluid collected by washing part of the lung. That is local fluid-based pharmacologic evidence. It isn’t lung-biopsy mRNA data or recent evidence of clinical benefit in patients. [33]

For muscle, look at Sarepta’s SRP-1001 and SRP-1003 together. The company describes an approach linking siRNA to a ligand that binds αvβ6 integrin. SRP-1001 targets facioscapulohumeral muscular dystrophy type 1 (FSHD1); SRP-1003 targets myotonic dystrophy type 1 (DM1). [26]

Sarepta’s March 25, 2026 presentation reported SRP-1001 concentrations in muscle and changes in a composite of DUX4-regulated downstream genes in MRI-guided biopsies. That composite isn’t a measure of how much DUX4 itself declined or proof of functional improvement. These are early exploratory results, with exclusions including samples below quantification limits. [27]

The same presentation’s safety population included 56 people, including placebo recipients. One serious event of chest discomfort was classified as severe and judged unrelated to the study drug. These were early results disclosed on March 25. The presentation date isn’t a substitute for a data cutoff or confirmation of long-term safety. [27]

For the brain, first distinguish the administration routes. Alnylam uses a lipophilic C16 conjugate for CNS delivery, and early mivelsiran (ALN-APP) trials used intrathecal administration, into the space containing cerebrospinal fluid. That route isn’t evidence that a subcutaneous injection crossed the blood-brain barrier. [28,29]

In an early analysis released by the company, ten patients with early-onset Alzheimer’s disease who received a single 75 mg dose had an average 73.5% reduction from baseline in cerebrospinal-fluid sAPPβ at one month. The 2025 material includes this 2024 interim analysis. It measures an APP-related protein in fluid, not mRNA in a human brain biopsy or improved cognition. [29]

Safety needs its own boundaries. Company data as of May 15, 2025 included procedural pain and headache, plus one fatal acute pancreatitis event judged unrelated to the drug. The company’s assessment that there were no drug-related severe or serious adverse events cannot be turned into “there were no deaths” or a definitive statement about the latest overall safety profile. [29]

Arrowhead’s ARO-MAPT, by contrast, aims to reach the CNS through systemic subcutaneous administration. The blood-brain-barrier penetration evidence cited in its September 29 announcement was preclinical. Human results remain something to evaluate—not an already established human brain-delivery success. [32]

Does Successful Delivery Mean Clinical Success?

Avidity offers an important counterexample. Del-desiran links a TfR1-targeting antibody to a DMPK-targeting siRNA to deliver treatment to muscle. DM1 is a progressive neuromuscular disease that can cause muscle weakness and impaired hand function. [10,22]

The original MARINA publication’s abstract, published in February 2026, reported muscle-biopsy DMPK mRNA reductions in 38 people with DM1. The six patients in the single-dose 1 mg/kg group had a 46% reduction at day 43. In the groups assigned to three-dose regimens, the nine patients receiving 2 mg/kg and 13 receiving 4 mg/kg had reductions of 44% and 37%, respectively, at day 92. The 10 placebo patients had a 0.9% increase. Different dosing schedules and assessment days prevent a simple efficacy ranking by dose. [30]

Safety was the primary endpoint. Two severe, serious adverse events and one participant’s discontinuation were reported. The material reviewed was the paper’s public abstract, which didn’t provide detailed causality assessments for those events. This is why target reduction in tissue and confirmation of patient function need to stay separate. [30]

On September 8, 2026, Novartis subsequently announced that phase 3 HARBOR had not shown statistically significant improvement versus placebo on its prespecified primary endpoint. Earlier target reduction in muscle biopsies didn’t guarantee success on the later functional endpoint. Extending that failure to every muscle-directed siRNA or antibody carrier would also go too far. [22]

Other RNA approaches compete in muscle. Dyne’s DYNE-101 links a TfR1-binding antibody fragment to an antisense oligonucleotide, or ASO. PepGen’s PGN-EDODM1 binds expanded CUG repeats. Both belong in the DM1 competitive picture, but neither should be counted as proof of successful human delivery of DMPK-degrading siRNA. [37,38]

Who Has the Technology—and Who Captures the Value?

Arrowhead and Sarepta can share exposure to the same muscle-delivery risk. An August 2026 filing states that Sarepta holds exclusive global licenses to assets including SRP-1001 and SRP-1003. Arrowhead receives milestones and tiered royalties on net sales, with the upper end described as the low double digits. Arrowhead doesn’t retain the entire product revenue stream. [31]

The same filing shows that Sarepta exercised rights to take over certain clinical-trial responsibilities and that voluntary termination provisions apply before approval. Arrowhead has also raised capital through convertible debt and share issuance. Partner execution, future funding, and dilution remain investment risks alongside delivery performance. [31]

Alnylam’s assets don’t all have the same rights structure either. Its 2025 Form 10-K says it holds global development and commercialization rights to mivelsiran, while ALN-HTT02 is being developed with Regeneron. One platform name doesn’t imply one profit-sharing arrangement across every product. [28]

Arrowhead’s May 2026 PNPLA3 deal is a concrete example. Madrigal obtained an exclusive global license to the asset, now MGL-0795, for $25 million upfront, up to $975 million in conditional milestones, and royalties. That is an asset license—not ownership of every way to target PNPLA3, and not $1 billion already collected. [73,77]

On September 15, Arrowhead also reported early results for ARO-DIMER-PA, which targets PCSK9 and APOC3 together. The company reported protein and lipid reductions. The disclosed detail on analysis populations, time points, and placebo adjustment isn’t sufficient here to rank it across trials or infer cardiovascular-event prevention. [80]

Dicerna ceased independent Nasdaq trading after Novo completed its acquisition in December 2021. Novartis completed the Avidity acquisition in February 2026. Attractive technology and an independently purchasable stock are separate questions. [3,9]

The City/Biogen CNS collaboration and ADARx/AbbVie tissue-delivery collaboration are worth tracking. But the agreements reviewed here don’t establish extrahepatic human delivery success for those programs, and City is private. DTx’s FALCON illustrates another fatty acid–siRNA approach, but the evidence obtained here is limited to its preclinical status at the 2023 acquisition. [34,35,36]

Approved Products and Real Competition Still Matter

A focus on delivery expansion shouldn’t leave out commercialization. Alnylam reported 74% year-over-year growth in second-quarter 2026 product revenue, while cutting its full-year TTR product revenue guidance from $4.4–$4.7 billion to $4.2–$4.5 billion. The company said second-line demand had normalized after an initial period of pent-up demand. [12]

AMVUTTRA is given subcutaneously every three months, with precautions concerning reduced vitamin A levels and supplementation. In the same US ATTR-CM market, the TTR stabilizer acoramidis (ATTRUBY) is approved as a twice-daily oral treatment. Treatment burden matters, but separate trials don’t establish which drug is more effective. [11,21]

Expectations and outcomes also diverged for Alnylam and Roche’s hypertension candidate zilebesiran. In the 2025 KARDIA-3 announcement, the 300 mg group had a placebo-adjusted 5.0 mmHg reduction in office systolic blood pressure at three months, with a nominal p-value of 0.0431. Yet the overall study missed its prespecified statistical-significance criterion after accounting for multiple tests. One p-value below 0.05 doesn’t make the entire trial a success. [13]

Arrowhead has REDEMPLO (plozasiran), approved by the FDA in November 2025. Its indication is as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare inherited disorder involving impaired triglyceride breakdown. The dose is 25 mg subcutaneously every three months. [14,15]

In August 2026, the company reported that SHASTA-3 and SHASTA-4 randomized a total of 757 people with severe hypertriglyceridemia (sHTG). In the groups receiving 25 mg every three months, median triglycerides at month 12 fell 79% and 81% from baseline, respectively. Those aren’t placebo-adjusted reductions. The company’s topline announcement alone doesn’t let us calculate the absolute size of complication prevention. [16]

This market also includes Ionis’s ASO TRYNGOLZA (olezarsen). Its June 2026 US label includes reducing triglycerides and acute pancreatitis risk in adults with sHTG and triglycerides of at least 500 mg/dL. It’s administered subcutaneously once monthly. REDEMPLO’s dosing interval may be an advantage to investigate, but superiority in efficacy or safety hasn’t been established against that competitor. [17]

Silence: Turning Liver Delivery into Disease Control

Silence Therapeutics (SLN) deserves a closer look as an independent developer. Its mRNAi GOLD platform uses GalNAc to deliver siRNA through ASGPR receptors on liver cells. Having proprietary chemistry and delivering more precisely in humans than Alnylam are different claims. This review didn’t obtain direct comparative evidence supporting the latter. [39]

The central asset is wholly owned divesiran (SLN124). It targets polycythemia vera (PV), a myeloproliferative neoplasm in which too many red blood cells are produced. Phlebotomy removes blood to reduce that burden. Divesiran lowers liver TMPRSS6, increasing the iron-regulating hormone hepcidin and restricting iron available to bone marrow. It addresses a marrow disease without delivering siRNA directly to the marrow. [18,40]

Look at the company’s August 2026 phase 2 SANRECO announcement. In the 36-week double-blind trial, 48 phlebotomy-dependent patients were randomized to 6 mg/kg divesiran every six or 12 weeks, or placebo. The primary endpoint combined absence of phlebotomy and hematocrit below 45% during weeks 18–36. Pooled response rates were 88% for treatment and 19% for placebo (p<0.0001). [18]

Keep the dosing intervals separate. Response rates were 93.8% with six-week dosing and 81.3% with 12-week dosing. Calling this an “88% response with quarterly dosing” would be inaccurate. Silence reported two grade 1 anemia events and transient injection-site reactions, with no new safety findings. Better phlebotomy and blood-count measures in 48 people don’t establish long-term prevention of thrombosis or a survival benefit. The full clinical dataset still matters. [18]

Competition is already here. On August 28, 2026, the FDA approved Takeda’s hepcidin-mimicking peptide Mimrylo (rusfertide) for erythrocytosis in adults with PV. It uses a weekly subcutaneous schedule, with higher doses split into multiple injections. The existing treatment landscape also includes phlebotomy and hydroxyurea, interferon, and ruxolitinib. [19,41]

Another major candidate, zerlasiran (SLN360), targets liver LPA to lower lipoprotein(a), or Lp(a). In the phase 2 ALPACAR-360 trial of 178 people with cardiovascular disease and high Lp(a), the 450 mg every-24-weeks group had a placebo-adjusted, time-averaged reduction of 85.6% through week 36 (95% confidence interval: an 80.3%–90.9% reduction). That’s neither a single-day measurement nor a reduction in heart attacks or strokes. [42,43]

That distinction has become more important. On September 4, Novartis announced that the 8,323-participant phase 3 Lp(a)HORIZON trial lowered Lp(a) but missed the statistical goal for its primary composite cardiovascular-event endpoint. Pelacarsen is an ASO, while zerlasiran is an siRNA; this isn’t a failure of the same drug. It does challenge the assumption that lower Lp(a) automatically delivers fewer clinical events. [44]

Competitors include Amgen, running phase 3 OCEAN(a)-Outcomes with olpasiran, and Lilly, running phase 3 ACCLAIM-Lp(a) with lepodisiran. Silence’s 2026 filing says it is seeking a partner for zerlasiran’s phase 3 development and commercialization. Being ready for phase 3 doesn’t mean phase 3 has started. [43,45,46]

Separate the dates when looking at funding. Silence had $72.054 million in cash and cash equivalents at the end of June. On August 14, it issued 14,907,407 American Depositary Shares and raised approximately $201.3 million before expenses. That added development capacity and diluted existing ownership. Adding the two figures wouldn’t give us cash as of October 1. Nor should first-half spending, affected by items including tax refunds, be mechanically extended into a runway estimate. [43,47]

Partnership history needs filtering too. In March 2026, AstraZeneca notified Silence that it wouldn’t develop SLN312 beyond phase 1. Silence said it expected to regain rights afterward. Past Mallinckrodt and Hansoh programs also have discontinuation or termination histories, so they can’t simply be listed as current backers. Divesiran’s ownership matters, but old partner logos don’t guarantee today’s development funding. [40,43,48,39]

Wave: Changing Fat Signaling Without Delivering Directly to Fat

Wave Life Sciences’ (WVE) WVE-007 is a GalNAc-siRNA using its SpiNA design to target liver INHBE. It aims to lower liver-derived Activin E signaling and influence the ALK7-related pathway in fat cells. A reduction in visceral fat therefore wouldn’t prove direct delivery into those cells. [49]

In the company’s March 2026 announcement, the single-dose 240 mg cohort had 32 participants randomized 3:1 and an average body mass index (BMI) of 32. At six months, placebo-adjusted results were a 14.3% reduction in visceral fat measured by DEXA body-composition scanning (p<0.05), a 5.3% reduction in total fat, a 2.4% increase in lean mass, and a 0.9% reduction in body weight. Visceral-fat loss isn’t weight loss, and increased lean mass isn’t a direct measurement of stronger muscles. [50]

A higher dose didn’t improve every number. At three months, placebo-adjusted changes in the 400 mg cohort were a 5% reduction in visceral fat, a 0.7% reduction in total fat, and a 0.2% decline in lean mass. But that follow-up differs from the 240 mg group’s six months, so a simple dose-failure verdict would be premature. Early company safety data through February 27 showed no serious treatment-emergent adverse events, discontinuations, or deaths through 600 mg. Repeat-dose and long-term safety still need follow-up. [50,49]

On September 23, the company announced initiation of a phase 2a combination trial with tirzepatide. Tirzepatide acts on GIP and GLP-1 receptors and is approved for weight management in the US. Wave therefore needs to show what it could add in combination, as well as what it could offer as an alternative. Arrowhead’s INHBE candidate and its direct fat-cell ALK7 approach are competing paths. Silence’s INHBE candidate SLN098 remains preclinical and shouldn’t be placed at the same stage. [25,51,52,53]

Wave had approximately $490.6 million in cash, cash equivalents, and marketable securities at the end of June. That money isn’t dedicated to WVE-007. WVE-006 and WVE-008 are RNA-editing assets, a different modality from siRNA. Counting all of a multi-technology company’s funding as the value of one siRNA candidate would distort the picture. WVE-007’s detailed contractual economics are another item to examine before investing. [54,55]

Vir: Executing with a Licensed Asset

Vir Biotechnology’s (VIR) elebsiran is a hepatitis B virus (HBV)-targeting siRNA licensed from Alnylam. Hepatitis D virus (HDV) depends on HBV infection. Vir combines elebsiran, which reduces production of the required hepatitis B surface antigen (HBsAg), with its own entry-blocking antibody tobevibart. The investment case centers on the combination’s clinical value more than on a newly invented proprietary delivery platform. [56,57]

Part 3 of the open-label phase 2 SOLSTICE trial randomized 67 participants. Two assigned to antibody monotherapy withdrew before dosing, leaving 32 combination recipients and 33 monotherapy recipients in the treated analysis. The combination used 300 mg tobevibart plus 200 mg elebsiran every four weeks; monotherapy used 300 mg tobevibart every two weeks. Because even the antibody schedules differed, this wasn’t a clean isolation of the effect of adding siRNA. [58]

The original paper’s week-24 primary-endpoint response was numerically lower with the combination: 15 of 32 participants (47%), versus 23 of 33 (70%) with the antibody alone. This composite required HDV RNA below the detection limit or a reduction of at least 2 log10 IU/mL from baseline, together with normalization of the liver enzyme ALT. This small trial used descriptive statistics without prespecified hypothesis testing, so it doesn’t establish statistical inferiority. But we shouldn’t omit that contrary result and tell only a combination-success story. [58]

The company later reported undetectable RNA in 28 of 32 combination recipients (88%) at week 96. That’s a later result with a different definition from the week-24 composite. Potential for sustained viral suppression and confirmed clinical value remain separate. Through week 48 in the original paper, 81% of combination recipients and 94% of monotherapy recipients had an adverse event, most commonly flu-like symptoms and chills. Those aren’t serious-adverse-event rates or proof of superior safety. [59,58]

There’s already a US-approved competitor. On May 22, 2026, the FDA approved Gilead’s Hepcludex (bulevirtide) for adults with chronic HDV without cirrhosis or with compensated cirrhosis. The US regimen is 8.5 mg subcutaneously every day. It received accelerated approval based on RNA and ALT surrogate measures; a benefit on disease-related clinical outcomes hasn’t been established. Vir’s monthly combination raises a treatment-burden question, but efficacy superiority requires direct comparative evidence. [56,57,60]

Rights and funding are separate considerations. Vir bears development costs for the Alnylam-licensed asset and has future conditional milestone obligations. It licensed commercial rights in Europe, Australia, and New Zealand to Norgine. The approximately $1.01 billion in cash, cash equivalents, and investments at the end of June funds the whole company, including oncology. It isn’t all siRNA funding, and Vir doesn’t retain all worldwide sales economics. [61,59,62]

Company Guidance and Unconfirmed Timelines

For delivery expansion, Arrowhead has scheduled its ARO-MAPT phase 1/2a interim-data webinar for October 14 at 11:30 a.m. PDT. Alnylam plans to present initial ALN-HTT02 results at EHDN on October 23 and hold a webinar on October 26. These are dates to assess results, not promises of clinical success or approval. [32,12]

Silence expected to start a phase 3 trial of divesiran every 12 weeks in the first half of 2027. Its filing, based on June cash before the August offering, projected funding into 2028 under its operating plan. That doesn’t confirm that the entire divesiran phase 3 program is funded. Watch the actual phase 3 design and start, the full phase 2 dataset, post-offering spending plans, and a zerlasiran partnership agreement. [18,43]

Wave guided to additional single-dose 600 mg data and initiation of a maintenance trial in the second half of 2026. Separate those planned events from the combination-trial start it has already announced. Its cash-runway guidance extends into the third quarter of 2028, excluding future GSK milestones. That doesn’t guarantee successful follow-up trials or funding for every development expense. [52,55]

Vir expected phase 3 ECLIPSE 1 topline data in the fourth quarter of 2026 and ECLIPSE 2 and 3 results in the first quarter of 2027. ECLIPSE 1 uses deferred treatment as its comparator. ECLIPSE 2 examines switching patients whose response to bulevirtide is inadequate. ECLIPSE 3 is a phase 2b head-to-head comparison with bulevirtide. The questions and populations differ. Vir guided to runway into the second half of 2028. These aren’t fixed readout dates or approval timelines. [56,59]

Arrowhead said on July 27 that YOSEMITE, its phase 3 zodasiran study in 70 people with homozygous familial hypercholesterolemia, had completed enrollment. The company expects study completion in mid-2027, with an LDL endpoint measured over 12 months. That isn’t a promised results or approval date. Silence’s SLN098 and SLN365 remain preclinical, with potential investigational new drug submissions in 2027; they aren’t clinical leaders yet. [68,51]

Here’s how the three developers compare. “Small” here distinguishes their development and business stage from the leading commercial companies; it isn’t a market-cap ranking. Timelines and runway are company guidance. The real investment question is which risks you’re prepared to take. [39,40,18,43,47,49,50,52,55,54,56,61,58,59,62]

Company	Business thesis being chosen	Current human evidence	Next company-guided catalyst	Capital and rights to examine
Silence	Its own liver platform and disease control with divesiran	Phase 2 in 48 people with PV; phlebotomy and blood-count measures	Phase 3 start expected in the first half of 2027; zerlasiran partner unconfirmed	June cash of $72.054 million and August gross offering proceeds of $201.3 million are separate; divesiran is wholly owned
Wave	Obesity and body-composition effects through liver signaling	Early, small WVE-007 samples; distinguish weight from fat measures	Additional 600 mg data in the second half of 2026; phase 2a combination-trial start announced	Approximately $490.6 million in June cash and securities supports multiple technologies; detailed economics need further review
Vir	Late-stage validation of a licensed siRNA plus its own antibody	Contrary week-24 SOLSTICE composite result alongside subsequent week-96 suppression	ECLIPSE 1 in the fourth quarter of 2026; ECLIPSE 2 and 3 in the first quarter of 2027, as expected by the company	Approximately $1.01 billion at June-end is company-wide funding; Alnylam payment obligations and Norgine regional rights matter

My Insights and Expectations

Ultimately, the most important factor in this business appears to be how precisely siRNA can be delivered to the target tissue.

My expectation is that companies that establish an early lead in ALK7 or other new targets could have substantial upside potential. This is a hypothesis about the opportunity available to early developers, rather than an established investment outcome.

Analysis and Outlook

Applying that lens, Arrowhead remains the first company to investigate if expanding delivery beyond the liver is the priority. It has different kinds of human evidence in adipose-tissue mRNA, local lung fluid, and partner muscle biopsies. But small samples, repeat dosing, functional benefit, partner rights, and still-unproven systemic human brain delivery all need to be reflected in the price one is willing to pay. [25,27,31,32,33]

Alnylam is the benchmark if proven clinical benefit and commercial maturity matter most. Early CNS pharmacologic evidence adds to disease-event evidence from approved products. Its lower sales guidance and KARDIA-3’s missed statistical goal still matter. Maturity doesn’t mean every pipeline program will succeed. [11,12,13,29]

Among development-stage companies, I would start a deeper investigation with Silence’s divesiran. It brings together asset ownership, clear PV-management measures, a placebo-controlled phase 2 signal, and subsequent financing. The key isn’t calling it “the next Arrowhead.” It’s whether the 12-week regimen holds up in phase 3 and remains competitive on anemia, long-term management, and access. [40,18,19,41,47]

Silence’s upside scenario requires phase 3 replication, a competitive treatment burden, and reasonable development costs and partnership terms. Weaker efficacy, safety problems from iron restriction, insufficient differentiation from an approved competitor, delays, or further dilution would lower that assessment. A major zerlasiran deal or takeover shouldn’t be treated as guaranteed value in the base case. [18,19,41,43,44,45,46,47]

Wave is a candidate for investors willing to assess an early obesity target’s additional potential. Its position could improve if the visceral-fat signal translates, in larger samples, into meaningful weight, metabolic, functional, and durable benefits—and adds value to tirzepatide. If the story remains limited to body-composition changes or the combination adds little, expectations should come down. Today’s evidence isn’t comparable in maturity to that of the leading obesity drugs. [50,49,52,55,53]

Vir is a candidate when the focus is a nearby late-stage clinical test. The question is whether the elebsiran combination delivers sufficient viral suppression, safety, and practicality, more than whether Vir owns an exclusive new carrier. Confirmatory trials need to resolve the different pictures shown by the week-24 composite and week-96 follow-up measures. Failure would call for a fresh valuation. [56,58,57,60,62]

These differences also help explain continued dealmaking. Buyers can be seen as seeking to apply a liver-validated approach to new targets, reach tissues such as muscle and brain, or secure the potential for longer dosing intervals. Deal value still can’t substitute for successful delivery. Acquisitions, technology options, and asset licenses also have different economics. [1,2,4,5,6,7,8,10,11,15,31]

Owning all five companies wouldn’t fully diversify the science. Liver delivery, shared targets, and assets connected through partnerships can overlap. After delivery capability, examine patient benefit, safety, contractual rights, and follow-up trial costs. Approval prospects should be assessed through each product’s confirmatory evidence, rather than assigned to an entire company. [25,30,22,31,39,49,56,61]

For that new-target thesis, Arrowhead’s human adipose-tissue ALK7 evidence and Wave’s early INHBE data and combination program deserve close attention. But Alnylam has already initiated phase 1 for ALN-6222. INHBE isn’t an empty field reserved for small companies. Silence’s SLN098 and SLN365 offer preclinical possibilities, not the same level of confidence as human clinical evidence. [25,51,52,12]

An early lead becomes more valuable if human delivery is followed by meaningful clinical benefit, repeat-dose safety and durability, and economic rights the company retains. The PNPLA3 transaction shows that a new-target asset can attract a real deal. It doesn’t show that competitors are blocked from the target. Without a patent and freedom-to-operate review, it would be wrong to value an early lead as a monopoly. [73,77,12,22,31]

Better delivery can still lead to limited patient benefit or face a more convenient competitor. Oral PCSK9 competition, HARBOR’s failure, and Silence’s terminated partnerships all belong in the downside case. If the share price already assumes success, or substantial dilution comes before proof, a promising target may still make a disappointing stock. [67,22,43]

This isn’t a buy ranking at today’s prices. Share prices, enterprise values, and a personal loss budget haven’t been evaluated, so attractive technology can’t be equated with undervaluation. Before adding to a position, ask whether new evidence reduces the failure case, whether funding reaches the next meaningful test, and whether competition, rights, or the loss you can absorb have changed. The old average purchase price isn’t the starting point.

That leaves ARWR for delivery expansion, ALNY for clinical and business maturity, SLN for a focused clinical thesis around its own asset, WVE for early obesity expansion, and VIR for nearby late-stage validation. Next, watch how brain-delivery data, divesiran’s phase 3 design, WVE-007 follow-up and combination data, and ECLIPSE results change those theses. Choosing a good siRNA company means asking both where the drug goes and what improves after it gets there—and who captures that value. [32,12,18,52,55,56]

This comparison focuses on US approvals, representative delivery technologies, and Silence, Wave, and Vir. It isn’t an exhaustive global review of companies, patents, freedom to operate, or manufacturing costs. Some clinical evidence is limited to company topline announcements or early data. RAGE evidence includes historical pharmacologic measurements; GPR146 remains preclinical. Gaps remain in current recruitment status, complete safety data, and full contractual terms. This is information and conditional analysis, not individualized investment or treatment advice.

References

1. Whole-Body Physiologically Based Pharmacokinetic–Pharmacodynamic Modeling for Interspecies Translation and Mechanistic Characterization of Plasma and Tissue Disposition of GalNAc-siRNAs — 2025
2. Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform — 2021-11-18
3. Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition — 2021-12-28
4. Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran — 2023-07-24
5. Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs — 2024-11-26
6. AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas — 2025-05-14
7. Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement — 2025-09-02
8. Novartis agrees to acquire Avidity Biosciences an innovator in RNA therapeutics strengthening its late-stage neuroscience pipeline — 2025-10-26
9. Novartis successfully completes acquisition of Avidity Biosciences strengthening late-stage neuroscience pipeline and advancing xRNA strategy — 2026-02-27
10. Avidity — DM1 disease and pipeline overview
11. AMVUTTRA Prescribing Information — 2025-03
12. Alnylam — Second-Quarter 2026 Financial Results and Recent Progress (July 30, 2026)
13. Roche — KARDIA-3 Results and Phase 3 Development Decision (August 30, 2025)
14. FDA approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome — 2025-11-18
15. REDEMPLO Prescribing Information — 2025-11
16. Arrowhead — Phase 3 SHASTA-3 and SHASTA-4 Results (August 30, 2026)
17. TRYNGOLZA Prescribing Information — 2026-06
18. Silence — Phase 2 SANRECO Topline Results for Divesiran (August 10, 2026)
19. FDA — Approval of Mimrylo for Polycythemia Vera (August 28, 2026)
20. Andrew Marshall, Nature Biopharma Dealmakers — Delivering on RNA Therapeutic Deals (2025)
21. FDA — ATTRUBY US Prescribing Information (November 2024)
22. Novartis provides update on del-desiran Phase III HARBOR study — 2026-09-08
23. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape — 2013-06-23
24. Imaging small molecule-induced endosomal escape of siRNA — 2020
25. Arrowhead Announces Interim Clinical Data on RNAi-based Obesity Candidates — 2026-01-06
26. Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 — 2026-03-25
27. Sarepta Clinical Results and Plan Forward: SRP-1001 for FSHD1 / SRP-1003 for DM1 — March 25, 2026
28. Alnylam 2025 Form 10-K — 2026-02
29. Mivelsiran: Phase 1 Study — 2025-08-05
30. An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1 — NEJM, February 19, 2026; original abstract in coauthor John Day’s Stanford profile
31. Arrowhead Form 10-Q quarter ended June 30 2026 — 2026-08-04
32. Arrowhead to Host Webinar with Interim Clinical Data from ARO-MAPT Phase 1/2a — 2026-09-29
33. ARO-RAGE: Pre-Clinical and Clinical Overview — not established; data cuts July 2023
34. Biogen and City Therapeutics Announce Strategic Research Collaboration — 2025-05-27
35. Novartis builds neuroscience pipeline with acquisition of DTx Pharma — 2023-07-17
36. AbbVie and ADARx collaboration and license option agreement — 2025-05-14
37. Dyne receives FDA Fast Track designation for DYNE-101 — 2025
38. PepGen Reports Second Quarter 2026 Results — 2026-08-06
39. Silence Form 10-K FY2025 — 2026-03-05
40. Silence divesiran EHA2026 follow-up — 2026-06-11
41. MIMRYLO US prescribing information — 2026-08
42. Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial — 2024-11-18
43. Silence Form 10-Q quarter ended June 30 2026 — 2026-08-10
44. Novartis Lp(a)HORIZON Phase III topline results — 2026-09-04
45. Amgen second-quarter 2026 results — 2026-08
46. Lilly Q2 2026 Earnings Slides — 2026-08
47. Silence closes upsized public offering — 2026-08-14
48. Silence full-year 2023 results and business highlights — 2024-03-13
49. INLIGHT Interim Phase 1 Investor Presentation — 2026-03-26
50. Wave Form 8-K / INLIGHT March 26 release — 2026-03-26
51. Silence second-quarter 2026 financial and business results — 2026-08-10
52. Wave initiates WVE-007 tirzepatide combination trial — 2026-09-23
53. FDA approves Zepbound for chronic weight management — 2023-11-08
54. Wave Form 10-Q June 30 2026 — 2026-07-30
55. Wave second-quarter 2026 results — 2026-07-30
56. Vir Q2 2026 corporate update — 2026-08-05
57. FDA approves first treatment for chronic HDV — 2026-05-22
58. Asselah et al. A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D (NEJM original PDF copy hosted by NATAP) — 2025-11-09 online;2026-01-22 print
59. Vir second-quarter 2026 earnings release — 2026-08-05
60. Gilead FDA accelerated approval of Hepcludex — 2026-05-22
61. Vir Form 10-Q June 30 2026 — 2026-08-05
62. Vir Fourth Quarter and Full Year 2025 Financial Results — 2026-02-23
63. LEQVIO prescribing information — 2026-08
64. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol — 2006
65. Teaming with insight — 2018-06-19
66. REPATHA prescribing information — 2026-07
67. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol — 2026-07-17
68. Arrowhead completes enrollment of global phase3 YOSEMITE zodasiran study — 2026-07-27
69. EVKEEZA prescribing information — 2025-09
70. OXLUMO prescribing information — 2025-04-07
71. RIVFLOZA prescribing information — 2025-03
72. GIVLAARI prescribing information
73. Arrowhead licenses clinical MASH program ARO-PNPLA3 to Madrigal — 2026-05-05
74. GSK Q2 2026 pipeline assets and clinical trials report — 2026-07-28
75. WEGOVY prescribing information — 2025-08
76. REZDIFFRA prescribing information — 2024-03
77. Madrigal pipeline
78. Activin E is a transforming growth factor beta ligand that signals specifically through activin receptor-like kinase 7 — 2024-04-10
79. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity — 2022-07-27
80. Arrowhead announces interim topline clinical results for ARO-DIMER-PA — 2026-09-15

As of October 1, 2026 (KST)

We already have once-weekly obesity drugs. So why do Novo Nordisk and Eli Lilly keep exploring technologies that last even longer? Let’s work through the practical reasons: helping patients tolerate treatment, reach a useful dose, and stay on it. Then we’ll look at the deals, release mechanisms, drug losses, and manufacturing challenges.

In this article

Verified Data

Start with a simple idea: the same drug can become a different product if its delivery schedule changes. In the US, injectable Wegovy and Zepbound are once-weekly products. Their active ingredients, semaglutide and tirzepatide, are already designed to remain in the body for a relatively long time. [1, 2]

Two approaches need to stay separate. One makes the drug molecule last longer. The other makes a reservoir under the skin release the drug gradually. Think of a sink: one slows the drain, while the other controls the faucet. The body is more complicated, but separating drug input from removal makes the rest much easier to follow. [1, 16, 17]

There is some evidence that fewer injections can help people stay on treatment. In the US STAY observational study of people with type 2 diabetes, weekly GLP-1 injections were associated with better persistence and adherence than daily injections. This wasn’t a randomized trial, though, and it doesn’t establish the same benefit for monthly obesity drugs. [3]

A quick terminology note: GLP-1, GIP, and amylin identify different signaling targets. A receptor agonist activates the receptor that receives a signal. Dual and triple agonists target multiple receptors. You don’t need to memorize every name. Just keep the drug’s targets separate from the technology used to deliver it over time. [2, 7, 25]

That doesn’t establish that less frequent dosing automatically means higher sales. What we can verify is that both companies have signed or evaluated multiple long-acting technologies. Whether convenience becomes better persistence and a stronger business will depend on the product. [4–9]

The problem patients still face: getting started and staying on treatment

Titration means increasing the dose in steps to help the body adjust. The basic US Wegovy injection schedule spends four weeks each at 0.25, 0.5, 1, and 1.7 mg before maintenance begins in week 17. Zepbound starts at 2.5 mg for four weeks, then moves to 5 mg, with further increases if needed after at least four weeks at the current dose. Both labels link gradual escalation to reducing gastrointestinal side effects. [39, 40]

These schedules illustrate a development challenge, not personal dosing instructions. Wegovy 2.4 mg is the comparison example in this article, not its only maintenance dose or maximum dose. Nor does every Zepbound patient need to reach 15 mg; response and tolerability matter. [39, 40]

Tolerability is about whether someone can live with the side effects and continue treatment. In Zepbound’s approval trials, gastrointestinal reactions caused some patients to stop. Nausea, vomiting, and diarrhea occurred mainly during escalation and declined over time. A drug working and a patient being able to keep taking it are separate questions. [40]

Analysis and Outlook: The Practical Value of Longer-Acting Delivery

The first development goal is to maintain useful drug exposure while avoiding an excessive initial concentration spike. Cmax is the highest concentration in the blood. If controlled release can soften a problematic early peak, developers can test whether that reduces nausea or vomiting while preserving useful exposure. That’s a design hypothesis, not a demonstrated benefit of every monthly formulation. [17, 41]

A lower Cmax alone doesn’t establish better safety. In the FDA’s Wegovy exposure–response review, the proportion reporting gastrointestinal events largely leveled off across the exposure range associated with 2.4 mg; the review identified dose escalation as a possible explanation. Average exposure, the way concentration rises, the escalation schedule, and differences between patients all matter. Lowering the peak by itself has not been shown to guarantee fewer side effects. [41]

The second goal is simpler or faster titration. Fewer dose changes, fewer calendar weeks to maintenance, and fewer injections are three different things. A better release profile might make adjustment easier and allow useful exposure sooner. But putting a month’s supply under the skin doesn’t eliminate titration. A depot that keeps releasing drug can be difficult to adjust midway, making the starting regimen especially important. [33]

An actual development attempt—and its limits

Camurus’ CAM2056 illustrates the idea. In its reported Phase 1b study of 80 adults with overweight or obesity, treatment started with two doses two weeks apart, followed by two monthly doses. Camurus reported similar Cmax and a later peak at four times the weekly dose. More drug per injection needn’t produce a proportionately higher peak. This didn’t demonstrate lower Cmax or superior tolerability. [33]

Camurus suggested faster titration might be possible, but also reported a tendency toward more frequent and severe gastrointestinal events at the highest starting dose. That counterpoint matters. The study had a randomized active-controlled portion and a separate escalation portion; it wasn’t a simultaneous randomized comparison of every dose group establishing that faster initiation was better. [33]

When a patient benefit could become a business benefit

Here’s the business logic. If fewer patients stop or reduce their dose because of side effects, and more reach an effective dose and stay on it, a product could offer more than fewer injections. A better treatment experience could matter even with similar efficacy. But actual weight change, discontinuation, long-term persistence, price, and insurance access still need to be measured. This is an interpretation of the clinical-to-commercial opportunity, not a claim that Novo and Lilly publicly gave these reasons for every deal. [3, 33, 39–41]

Fewer administrations might also reduce the burden of remembering injection days and giving each dose. Products using single-use devices could need fewer devices and packages, although pens differ and implants add a procedure. Additional active ingredient, manufacturing losses, and sterile processing belong in the calculation too. One-quarter as many injections doesn’t mean one-quarter of the cost or four times the supply capacity. [6, 8, 35–38]

On a small screen, swipe the table sideways to read every column.

Development goal	How clinical and business value might emerge	Evidence actually needed
Soften an excessive early peak	Preserve efficacy while potentially reducing side effects and discontinuation	GI severity, duration, and discontinuation at comparable effective exposure
Simplify or accelerate titration	Reach maintenance sooner or reduce dose-change burden	Time to maintenance, proportion reaching it, discontinuation, and weight change
Reduce administrations	Ease daily-life treatment burden and potentially support persistence	Long-term persistence, satisfaction, and weight maintenance in obesity
Differentiate the product	Give patients another reason to choose it even if efficacy is similar	Comparisons that include price, insurance access, injection-site reactions, and usability
Apply a platform to several candidates	Create more combinations of future molecules and delivery technology	Stability, dose requirements, release, and clinical performance for each molecule
Reduce device and packaging burden	Potentially reduce demand for single-use devices	Total costs including API, devices, procedures, and manufacturing yield

Verified Data: Company Statements and Actual Deals

Let’s separate stated priorities from interpretation. When the TransCon deal was announced in 2024, Novo’s research executive described less frequent treatment as a research focus. Lilly’s Camurus agreement covers up to four compounds across several target classes, giving it room to evaluate delivery technology beyond one product. Buying multiple development options is a reasonable business interpretation—not evidence that every candidate will succeed. Novo’s TransCon collaboration was subsequently the subject of a termination announcement. [4–7]

The deal history shows the direction of interest

Keep licenses, evaluation agreements, and terminations separate. A license grants development or commercialization rights; an evaluation agreement lets a company assess the technology. A deal’s maximum stated value is also different from money already paid. [4, 6, 8, 9]

Milestones are payments triggered by specified development, regulatory, or sales achievements. Royalties are tied to product sales. An upfront payment comes at the beginning of a deal. The maximum possible proceeds and cash already received are different numbers. [4, 6, 9]

On a small screen, swipe the table sideways to read every column.

Announcement date	Parties and technology	What was announced	What to watch
November 4, 2024	Novo–Ascendis, TransCon	Lead monthly GLP-1 candidate; up to $285 million in upfront, development, and regulatory payments, plus sales milestones and royalties	Read alongside the later termination announcement. The entire amount wasn’t upfront. [4]
June 3, 2025	Lilly–Camurus, FluidCrystal	Exclusive worldwide rights for up to four Lilly compounds; up to $290 million in upfront, development, and regulatory payments plus $580 million in sales milestones, with royalties separate	The combined $870 million ceiling is conditional. [6]
June 1, 2026	Lilly–Camurus expansion	Exercise of the amylin receptor agonist option triggered an initial $5 million payment	Expansion of the existing agreement, not a fresh $870 million cash payment. [7]
July 7, 2026	Novo–Vivani, NPM-139	Nonexclusive evaluation agreement for a semaglutide implant	Neither an exclusive commercialization license nor an acquisition. [8]
September 14, 2026	Novo–Ascendis termination announcement	Ascendis announced termination, reversion of rights, and plans for its own development	Don’t assume every legal step finished that day. The release didn’t specify the reason for termination. [5]
September 24, 2026	Novo–Nanexa, PharmaShell	Up to five programs; potential payments totaling up to €1.165 billion	The €615 million component includes upfront, development, and regulatory payments. A separate upfront amount wasn’t disclosed. [9]

Be especially careful with the inference that Novo ended TransCon and then chose ALD because ALD was better. The announcement dates are verifiable; that causal explanation isn’t. Ascendis said it planned to advance monthly TransCon semaglutide after termination became effective and rights reverted. [5, 9]

Lilly also has an older termination example. On November 8, 2011, it and Amylin announced a mutual end to their exenatide alliance and a settlement of their litigation. Development and commercialization responsibility for Byetta and Bydureon would transfer to Amylin. This belongs to the history of type 2 diabetes, not a recent obesity-drug failure or a verdict against all microspheres. [10, 11]

The technologies extend delivery in different ways

Let’s put pictures to the names. Start with microspheres as tiny polymer beads, lipid depots as gels formed in the body, implants as reservoirs, and ALD as a thin shell around drug particles. The illustration explains structures; it isn’t drawn to scale or a blueprint for a specific product. [8, 12–15]

Microspheres: tiny polymer beads

Microspheres put portions of drug inside tiny biodegradable polymer beads. Water enters, drug diffuses out, and the polymer breaks down. PLGA is one polymer used for this approach. [12, 18]

Bydureon BCise, containing exenatide, is a real example: a weekly microsphere injection approved in the US for type 2 diabetes. It isn’t an example of approved monthly semaglutide for obesity. Experience with a platform doesn’t automatically validate a new ingredient or dosing interval. [12, 18]

Its PK is revealing. After one dose, surface drug releases first; further release as the microspheres hydrate and erode produces a blood concentration peak around weeks 6–7. With weekly dosing, concentrations build for roughly 10 weeks before reaching steady state. A weekly injection doesn’t mean every dose has finished releasing within a week. [12]

Making the beads is only part of the challenge. Polymer properties, manufacturing, storage, and interactions between drug and polymer can affect release. A good-looking laboratory curve still needs to translate into the body. Bydureon’s timetable also shouldn’t be applied to every microsphere product. [12, 18]

Lipid depots: a gel reservoir

Lipid depots take a different route. Camurus describes FluidCrystal as a drug-containing lipid liquid that forms an ordered liquid-crystalline gel when it encounters water in tissue. Drug then leaves this reservoir gradually. [13]

The Lilly–Camurus collaboration aims to apply that technology to Lilly compounds. The companies describe dual and triple agonists and the amylin class, but undisclosed candidates can’t be identified as tirzepatide or any other particular molecule. A gel structure alone doesn’t establish an absence of early burst or better efficacy. [6, 7, 13]

Implants: a reservoir under the skin

An implant places a small reservoir under the skin. Vivani’s NPM-139 is a semaglutide candidate using NanoPortal technology. A removable source is an interesting feature, but convenience has to include insertion and removal. [8]

Implants aren’t interchangeable machines. ITCA 650 used a DUROS osmotic pump: incoming water generated pressure that moved a piston and pushed out exenatide. Describing Vivani’s NanoPortal as having the same internal structure would be wrong. [8, 19]

ALD: a thin coating around drug particles

ALD stands for atomic layer deposition. Nanexa describes PharmaShell as building an extremely thin inorganic coating around microscopic drug particles. The coating’s composition, thickness, and dissolution characteristics are intended to control release. [14, 15]

Compare that with microspheres. A microsphere disperses drug within polymer; ALD coats the drug particle itself. PharmaShell’s micrometer-scale particles have nanometer-scale coatings—the whole particle isn’t necessarily a nanoparticle. The thick-looking shell in the illustration simply makes the distinction visible. [14, 21]

Nanexa highlights the potential to fit a high proportion of drug into the particles and reduce injection volume. It also presents controlled early release and protection of the drug as possible benefits. Actual volume, stability, and release performance need to be established for each substance. A thin coating doesn’t make clinical development automatically easy. [15, 21]

TransCon: a temporary linker and carrier

TransCon connects a drug, a temporary linker, and a carrier. As the linker breaks, the original drug is released. This is a different platform from ALD’s inorganic coating. The next illustration shows the general TransCon concept, not undisclosed structural details of its semaglutide candidate. [16]

Today’s weekly semaglutide matters here too. Albumin binding and resistance to enzymatic degradation help it persist; its elimination half-life is about one week. Tirzepatide’s is approximately 5–6 days. Drawing weekly Wegovy as a drug released by bursting microspheres would misrepresent how it works. [1, 2]

PK asks how much drug is present, and when

Pharmacokinetics, or PK, describes drug concentration over time. Release and absorption contribute to the input side; elimination removes drug. Drug effect concerns the biological response to that exposure. A concentration graph is therefore not automatically a weight-loss graph. [17]

Peaks, troughs, and total exposure

Cmax is the peak concentration; Tmax is the time to that peak. With repeated dosing, the trough concentration, Cmin, matters too. Look at both the peaks and the valleys. [17]

AUC is the area under the concentration curve, a measure of total exposure over time. Equal AUC can come from a brief high concentration or a longer lower one. Equal area alone therefore doesn’t establish equal efficacy or safety. Partial AUC examines exposure during a particular portion of the interval. [17]

A simple equation explains why. Assuming the same active drug, linear PK, and constant clearance, total single-dose AUC = bioavailability × dose ÷ clearance. Bioavailability, F, is the fraction of the administered dose reaching systemic circulation; clearance, CL, describes drug removal capacity. This is a mass-balance relationship under stated assumptions, not a company’s clinical result.

If F, dose, and CL are unchanged, slower delivery can leave the total area measured all the way to the end unchanged while altering the peak, trough, and early exposure. If the formulation changes F, the same dose needn’t produce the same exposure. This doesn’t give us a prescription rule for multiplying a weekly dose into a monthly one. [17]

How much intact drug survives the wait?

API means active pharmaceutical ingredient—the material responsible for the drug’s activity. Don’t assume all API placed under the skin reaches the blood intact. A 2018 original study observed enzymatic breakdown of GLP-1 analogs, including semaglutide, in homogenized subcutaneous tissue from humans, rats, and minipigs. This was an in vitro tissue experiment, not a measurement of the percentage lost from a monthly depot in patients. [32]

Separate the possible losses. Damage during manufacture or storage, chemical changes within a depot, and tissue-enzyme degradation after release but before blood entry are different processes. Research on another peptide, octreotide, found chemical modification inside PLGA; the evidence consulted here was the abstract, and it doesn’t give semaglutide the same loss rate. Intact drug still waiting inside a reservoir isn’t degraded drug. Elimination after blood entry is also different from loss before absorption. [18, 32, 34, 35]

Four doses of semaglutide 2.4 mg QW—every seven days—add up to 9.6 mg. For this example, “monthly” means exactly 28 days. That sum isn’t automatically a clinically equivalent dose given once every 28 days. The FDA label reports 89% absolute bioavailability for the existing subcutaneous injection; the other 11% cannot simply be assigned entirely to degradation under the skin. [31]

With the same active ingredient, constant clearance, and linear PK, matching only average steady-state exposure gives: 28-day dose = 9.6 mg × weekly-formulation F ÷ 28-day-formulation F. Using 89% for weekly F, a monthly F of 89% gives 9.60 mg; hypothetical values of 70% and 50% give 12.21 mg and 17.09 mg. Those monthly values are teaching assumptions, not measurements from a candidate. Matching the average also doesn’t match peaks, troughs, or safety. [17, 31]

The underlying model is average concentration = F × dose ÷ (CL × dosing interval). First-dose AUC over 28 days and repeated-dose steady-state exposure aren’t the same thing. This calculation isn’t a clinical dose-conversion guide.

The useful question is how much intact drug reaches the blood from this formulation. Lower monthly F could require more API. But the sources reviewed don’t establish a general rule that every monthly semaglutide formulation must use far more than 9.6 mg. Without degradation, release, and absorption data, we can’t specify the multiplier. [31–33]

CAM2056’s reported similar peak doesn’t establish API efficiency, absolute bioavailability, or equivalent steady-state total exposure. It therefore proves neither that four times the weekly dose is equivalent nor that subcutaneous losses are absent. [33]

Four numbers that should not be mixed up

Four numbers need to stay separate in the cost discussion. Manufacturing recovery and encapsulation efficiency describe how much input material is recovered or incorporated. Drug loading is API’s share of finished-particle mass. Dose is the API mass administered, and F is the fraction reaching systemic circulation intact. High loading may help reduce injection volume, but it doesn’t guarantee high F or low manufacturing cost. [15, 31, 35]

Check each study’s exact denominators for recovery and encapsulation efficiency. Peptide losses can add cost, but total product cost also includes processing time, sterile manufacturing, testing, and rejected material. Without product-level cost data, we can’t rank companies’ economics. [35]

A design using more API needs more specific safety questions. Extra mass isn’t automatically immediate systemic overexposure. Developers need to examine early release, Cmax, AUC, residual exposure, the nature and effects of altered material, and local reactions separately. This doesn’t establish that degradation products are toxic. It means testing what happens if drug added to compensate for expected losses releases differently from expectations. [17, 33, 34]

Burst, lag, and the long tail

Burst describes relatively rapid initial release, lag a delay before substantial release, and tail the exposure that persists afterward. An initial burst isn’t automatically a defect; distinguish it from unintended large-scale release, or dose dumping. The key question is whether the intended schedule is reproducible. [12, 17]

Lowering the peak isn’t always the right objective. Input could become too slow to reach useful exposure promptly, or late exposure could be insufficient. The figures deliberately avoid a universal GLP-1 “efficacy line” or “toxicity line.” Establishing those thresholds would require evidence for the particular drug and regimen. [17]

Half-life can be confusing too. When depot input is slower than elimination, the final decline in concentration can reflect the reservoir’s supply rate more than the molecule’s elimination rate. This is called flip-flop PK. A long tail doesn’t necessarily mean the molecule itself acquired a longer elimination half-life.

Repeated dosing and accumulation

Repeated dosing adds another issue: accumulation. A new dose arrives while some of the previous dose remains, and their contributions overlap. At steady state, the concentration pattern repeats from one dosing interval to the next. It doesn’t mean concentration is constant at every moment. [2, 12, 17]

This connects back to titration. A long-lasting supply combines the effects of old and new doses, so initiation, escalation, and stopping need to be evaluated as one timeline. The first injection’s peak can’t establish how manageable the entire treatment course will be. [17, 33, 39]

What removal can and cannot do

Removability also needs a precise reading. Even if removal completely stops further input, it doesn’t take drug already circulating out with it. For a slowly eliminated molecule such as semaglutide, concentration will decline afterward. “Removable” doesn’t mean its effects and side effects instantly disappear. [1, 8]

Is lasting longer enough for approval?

ITCA 650 is a historical counterexample. In August 2024, the FDA issued its final decision refusing approval of the exenatide implant application in its then-current form. Demonstrating safety and a favorable benefit–risk balance was a problem. Review documents also raised device performance, PK variability, manufacturing uniformity, and sterility-assurance issues. [19, 20]

This isn’t a verdict against all implants. It shows that a familiar drug can acquire new uncertainties through its delivery device and manufacturing process. Conversely, a changed device alone doesn’t establish the cause of a particular adverse event. [19, 20]

Moving from a small experiment to a large factory

Think of CMC—chemistry, manufacturing, and controls—as keeping materials, processes, and product quality consistent. Scaling microspheres requires control of mixing, shear, solvent removal, and drying. Changes can affect particle size and distribution, pores, drug distribution, and release. An original exenatide microsphere study found that pressure, temperature, stirring, and flow ratio affected size distribution, encapsulation, initial release, and residual solvent. That’s why batch consistency—getting the same quality from each production batch—matters. [18, 36, 37]

Separate changes to the polymer specification from changes caused by processing. Altering PLGA’s lactide:glycolide ratio, molecular weight, or end groups differs from polymer-chain breakdown during production. Deliberately changing raw-material specifications to preserve performance would create a separate comparability task. A preclinical naltrexone study found morphology and laboratory-release differences after pilot-scale expansion, but no statistically significant difference in in vivo PK. That isn’t proof of equivalence, yet it also shows why scale-up shouldn’t automatically be called failure. [18, 37]

That example involved another drug and preclinical pilot-scale production. It doesn’t establish the same outcome for commercial-scale GLP-1 manufacturing. [37]

ALD scale-up: uniformity is only part of the job

Uniform ALD films and economical mass production of uniform finished medicines are different achievements. Mixing must bring coating gases into contact with the powder; precursor pulses and gas-purging steps affect throughput. A particle-coating scale-up model examines mass transfer, reactor design, and possible improvements. It is a preprint, not a test establishing PharmaShell’s clinical failure or commercial success. The practical question is whether sufficient output and reasonable costs can coexist with coating consistency, drug stability, residue control, and sterile quality. [14, 18, 38]

These questions are more useful than asking which technology lasts longest. The right-hand column below lists evaluation requirements, not defects already demonstrated at particular companies. [1, 8, 12–19]

On a small screen, swipe the table sideways to read every column.

Approach	How it extends delivery	PK and practical questions
Microspheres	Diffusion and polymer breakdown release drug	Early burst, lag, tail, and manufacturing reproducibility
Lipid depot	Release from a liquid-crystalline gel formed on contact with tissue water	Release and absorption with the actual molecule; repeated-dose concentrations
Implant	An inserted reservoir provides ongoing input	Delivery consistency, insertion/removal burden, and exposure remaining after removal
ALD	Coating composition, thickness, and dissolution control drug availability	Injection volume at higher doses, human PK, and uniformity at scale
TransCon	Temporary linker cleavage releases the parent drug	Candidate-specific release, exposure, and repeated-dose results
Existing long-lived molecules	Albumin binding, degradation resistance, and related features	Elimination half-life, concentrations between doses, and escalation design

Company Guidance and Unconfirmed Timelines

For ALD, separate human observations from modeling. Nanexa’s May 2026 presentation distinguished early clinical proof of concept with liraglutide from semaglutide animal data and simulations of human PK. That isn’t evidence that monthly or quarterly semaglutide has demonstrated weight loss and long-term safety in humans. [21]

Monthly and quarterly administration in the September Novo–Nanexa announcement are development targets. A deal isn’t an approval, launch, or demonstration of the intended interval in patients. Undisclosed candidate-level clinical dates and results remain unknown. [9]

Manufacturing is another milestone to watch. On September 22, Nanexa and Forge Nano announced joint development of large-scale ALD equipment intended to meet good manufacturing practice, or GMP, requirements. Preparing to expand capacity is different from having validated commercial output and quality. [22]

Vivani’s six-to-twelve-month delivery is likewise a design target. Its August 13 update said enrollment and initial dosing of 20 participants were complete in the small, low-dose Australian Phase 1 SLIM-1 study. An early trial doesn’t establish six-month or yearly human dosing. [8]

Vivani projected topline data in November 2026 and Phase 2 in 2027. Camurus guided to starting Phase 2b for its own monthly semaglutide, CAM2056, in the second half of 2026. These are company plans; CAM2056 shouldn’t be conflated with Lilly’s undisclosed collaboration compounds. [8, 27, 28]

Verified Data: The Competition Includes More Than Long-Acting Injections

In US obesity treatment, daily pills compete too. The 2026 FDA label includes oral Wegovy, while Lilly’s Foundayo, orforglipron, was approved on April 1, 2026 for adult weight management. Less frequent injections have to compete with avoiding injections altogether. [1, 23, 24]

Other candidates use different molecular designs. Amgen’s MariTide combines an antibody and peptides to activate GLP-1 receptors and block GIP receptors; Amgen describes its Phase 3 MARITIME program as pursuing monthly treatment. Don’t confuse its GIP blockade with tirzepatide’s GIP activation. [2, 25, 26]

The table covers approaches directly relevant to this discussion and separates approved medicines from candidates. Some recruitment descriptions come from sponsors. Public registry records and all current statuses couldn’t be fully reconciled; this isn’t an exhaustive global competitive landscape. [1, 2, 8, 9, 23–28]

On a small screen, swipe the table sideways to read every column.

Category and developer	Product and approach	Population and status as of October 1, 2026	Next evidence to watch
Approved—Novo	Wegovy, GLP-1	US weight management; FDA labels for weekly injection and daily tablets	An established alternative for new long-acting candidates [1]
Approved—Lilly	Zepbound, GIP/GLP-1	Weekly US injection within its approved indications, including obesity	Benefits of a new formulation relative to the existing product [2]
Approved—Lilly	Foundayo, nonpeptide GLP-1	Daily oral treatment for US adults with obesity or overweight plus a weight-related condition	Convenience and persistence competition [23, 24]
Clinical—Amgen	MariTide, antibody–peptide	Phase 3 studies separating populations with and without type 2 diabetes; sponsor lists MARITIME-1/2 as active, not recruiting	Actual trial results and safety; no invented readout date [25, 26]
Early clinical—Camurus	CAM2056, lipid depot	Overweight/obesity; listed as Phase 1 in the company pipeline	Whether second-half Phase 2b initiation guidance is achieved [27, 28]
Early clinical—Vivani	NPM-139, implant	Australian trial; company reports initial dosing of 20 participants	November data target; longer human evidence remains separate [8]
Formulation development—Nanexa/Novo	PharmaShell, ALD	Monthly/quarterly targets; candidate-level phase and recruitment undisclosed	Progress from semaglutide animal/model data to human evidence [9, 21]

First align the disease, patient population, and treatment duration. Historical diabetes microspheres or pumps aren’t evidence of efficacy for a new obesity drug. Weight-loss percentages from unrelated trials don’t establish superiority, either. Oral and injectable milligram doses also aren’t directly comparable because absorption differs. [1, 12, 19, 25]

Where background reporting ends and interpretation begins

In 2025, BioPharma Dive and MedCity News covered Lilly–Camurus in the context of competition for longer-lasting metabolic treatments. That reporting helps explain the industry’s interest in dosing intervals. It doesn’t establish private motives for terminating a deal or prove which technology wins. [29, 30]

My Insights and Expectations

What I especially want to know is how much extra API a longer interval requires. If a formulation delivers a smaller fraction of intact drug into circulation, it may need more raw material and additional exposure and safety work. I see both manufacturing recovery and intact drug utilization in the body as potential weaknesses in the economics of peptide depots.

For microspheres, I think maintaining batch consistency as the process scales could be a substantial challenge. Raw-polymer specifications and processing-induced changes need separate examination. If developers change those specifications, showing that the resulting formulation performs consistently before and after the change could become an important CMC task.

For ALD, uniform coating alone doesn’t reassure me. I expect substantial hurdles in expanding atomic-layer coating while meeting throughput, cost, and product-quality requirements together. Commercial-scale output, yield, and consistent-quality data would change that assessment. The public evidence doesn’t justify declaring scale-up impossible.

Analysis and Outlook

The evidence suggests that what Novo and Lilly are buying is the option to make treatment easier to continue while managing side effects and titration burden. Weekly drugs can work well and still leave room for less burdensome delivery and product differentiation. That’s an investment interpretation, not an observed improvement in persistence or sales.

There may be no single winning platform. An implant could appeal to someone comfortable with insertion; an injectable depot to someone seeking a longer interval without implantation; a pill to someone avoiding needles. Efficacy, side effects, price, access, and administration burden will all shape the choice. Dosing frequency alone can’t tell us market share.

The positive scenario

The positive scenario is predictable human exposure, tolerable repeat dosing and escalation, and benefits large enough to justify injection or insertion. Add good API utilization, yield, reproducibility, and clinical progress, and a platform company’s deal value could become more tangible. The evidence accumulated matters more than a headline payment ceiling.

The negative scenario

The negative scenario is that prolonged release makes treatment harder to control. Unexpected early exposure, patient variability, accumulation, persistent exposure after stopping, poor API utilization, or manufacturing problems could erode the convenience advantage. If pills and existing weekly products are already convenient and accessible enough, the incremental value of longer intervals could also be smaller.

Stock expectations and regulatory prospects

For stock direction, distinguish the large drugmakers from the platform companies. Human data, retained partnerships, and development progress could raise expectations for a platform company; adverse outcomes could lower them. One delivery technology’s success won’t determine Novo’s or Lilly’s overall stock trajectory. This article hasn’t assessed current share prices or valuations.

The same discipline applies to regulatory prospects. A familiar ingredient or a big-pharma partner can’t simply be converted into an approval probability. ITCA 650 shows why safety, delivery performance, and quality can create separate hurdles. Look at the actual candidate’s clinical and manufacturing evidence, not just the platform name.

Evidence and milestones to watch

The evidence that would change the outlook includes human single- and repeat-dose PK, exposure during escalation and after stopping, patient variability, tolerability, API utilization, yield, reproducibility after scale-up, and practical treatment burden. Nearer-term watch points include Vivani’s projected November data and Camurus’ clinical-start progress. For ALD, watch how monthly and quarterly ambitions translate into human evidence. Timelines are guidance; success is a separate question. [8, 9, 21, 27, 28]

A falling share price doesn’t create an averaging-down thesis merely because the stock is cheaper than before. Reassess whether the core evidence still holds, whether new data reduce risk, the loss that could be tolerated if development fails, and concentration in one platform. Without personal portfolio information, there’s no basis here for specifying a stock or allocation to add.

A useful long-acting drug must do more than keep drug trapped for a long time. It needs to deliver a predictable amount at the right time, with a process that can be managed safely. Novo’s and Lilly’s deals can be read as a search for that possibility. Human concentration curves and clinical and manufacturing outcomes will tell us more about the value created than the size of the deal announcement.

This article explains technologies and public evidence. It isn’t an instruction to change personal treatment or execute an investment trade.

References

1. FDA: Wegovy prescribing information, February 2026
2. DailyMed: Zepbound prescribing information
3. STAY Study: Persistence and adherence with weekly versus daily injectable GLP-1 receptor agonists in US type 2 diabetes care
4. Ascendis and Novo Nordisk: TransCon collaboration announcement, November 4, 2024
5. Ascendis: Rights to TransCon in metabolic and cardiovascular diseases to revert after termination, September 14, 2026
6. Camurus and Lilly: Collaboration and license agreement for long-acting FluidCrystal incretins, June 3, 2025
7. Camurus: Expansion of Lilly collaboration, June 1, 2026
8. Vivani: Second-quarter 2026 business update, including NPM-139 and the Novo evaluation agreement
9. Nanexa: Novo license and collaboration agreement—company release distributed by MFN, September 24, 2026
10. Lilly and Amylin: Mutual termination of diabetes alliance, November 8, 2011
11. SEC EDGAR: Eli Lilly 2012 Form 10-K
12. DailyMed: Bydureon BCise prescribing information
13. Camurus: FluidCrystal injection-depot technology
14. Nanexa: What is PharmaShell?
15. Nanexa: Potential benefits of PharmaShell
16. Ascendis: TransCon technology
17. FDA: In Vivo Pharmacokinetic Bioequivalence Studies for Long-Acting Injectables—Considerations and Challenges
18. FDA: FY2016 Regulatory Science Report—Long-Acting Injectable Formulations
19. FDA: ITCA 650 advisory committee briefing document, September 21, 2023
20. Federal Register: Final Decision on the Proposal To Refuse To Approve ITCA 650, August 2024
21. Nanexa: PharmaShell monthly and quarterly semaglutide presentation, May 19, 2026
22. Forge Nano and Nanexa: ALD manufacturing joint development—company release, September 22, 2026
23. FDA: Foundayo prescribing information, July 2026
24. FDA: Foundayo approval announcement, April 1, 2026
25. Amgen: The Story of Maridebart Cafraglutide (MariTide)
26. Amgen: MARITIME clinical study program
27. Camurus: R&D pipeline
28. Camurus: CEO statement for the second quarter of 2026
29. BioPharma Dive: Lilly partners with Camurus in search of a long-lasting obesity drug
30. MedCity News: Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds
31. FDA: Wegovy prescribing information—subcutaneous bioavailability, Section 12.3
32. Original research: A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides
33. Camurus: CAM2056 Phase 1b topline results, November 10, 2025
34. Original research abstract: Effect of inner pH on peptide acylation within PLGA microspheres
35. Original research: Efficient aqueous remote loading of peptides in poly(lactic-co-glycolic acid)—full paper archived by the German National Library
36. Original research: Injectable sustained-release PLGA microspheres of exenatide prepared by supercritical fluid extraction of emulsion
37. Original research: Transitioning from a lab-scale PLGA microparticle formulation to pilot-scale manufacturing
38. Preprint: Modeling scale-up of particle coating by atomic layer deposition
39. Novo Nordisk: Wegovy US prescribing information, June 2026—initiation and escalation
40. Lilly: Zepbound US prescribing information, August 2026—escalation and gastrointestinal adverse reactions
41. FDA: Wegovy Clinical Pharmacology Review—exposure, gastrointestinal events, and escalation